---
$id: https://graph.org.ai/products/commodity/51151905
$type: Product
source: UNSPSC
code: "51151905"
title: "Carisoprodol"
class: "51151900"
classTitle: "Centrally acting skeletal muscle relaxants"
family: "51150000"
familyTitle: "Autonomic nervous system drugs"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Carisoprodol

**UNSPSC Code**: 51151905
**Class**: [Centrally acting skeletal muscle relaxants](Centrally acting skeletal muscle relaxants.mdx)
**Family**: [Autonomic nervous system drugs](../Autonomic nervous system drugs.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes a muscle relaxant with the molecular formula C12H24N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 21925K482H, chemically known as 1,3-propanediol, 2-methyl-2-propyl-, carbamate isopropylcarbamate (ester) but generally known as carisoprodol, which bears US NIH Compound Identifier 2576. European Medicines Agency schedules Carisoprodol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06631MIG. The term CARISOPRODOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules carisoprodol in its Anatomical Therapeutic Chemical (ATC) Classification. CARISOPRODOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule carisoprodol under HS 29241900 and SITC 51471. As of Q4 2014, CARISOPRODOL remains the US FDA Preferred Term for this commodity. Carisoprodol bears US NLM identifiers UMLS ID C0702216 and NCI Concept Code C28904. SMILES: O(CC(CCC)(COC(=O)N)C)C(=O)NC(C)C.

